American College of Cardiology (ACC) Oklahoma Chapter 2018 Annual Scientific Meeting

Saturday, May 12, 2018, 8:05 AM - 4:00 PM, Samis Education Center


The overall goal for this year’s conference is improvement of patient care through increasing learner competence, leading to improved performance in applying evidence-based use of evidence-based treatment options.

1. Describe the different mechanisms of mitral regurgitation and how they influence management.
2. Analyze the nuances of echo imaging in aortic stenosis and patient characteristics that determine management decisions.
3. Review the most recent update of the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines pertaining to native mitral and aortic valve disease.
4. Discuss the most recent American Association of Echocardiography (ASE) guidelines for native valve regurgitation and for aortic stenosis and how they influence patient care.
5. Discuss how to use appropriately cardiovascular magnetic resonance (CMR) techniques for the quantification of native valve regurgitation.
6. Evaluate prognosis of patients with valvular heart disease based on CMR findings.
7. Assess prosthetic valve disease (including transcatheter aortic valve replacement (TAVR)) using CMR techniques.
8. Identify the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence.
9. Explain the differences in coronary artery disease patterns in women and its impact on prognosis.
10. Recognize sex-specific risk factors that affect women that should be part of risk assessment of women.
11. Describe recommendations for specialized care for women to prevent and treat cardiovascular disease.
12. Review the methodology of developing performance and quality measures.
13. Discuss the construct and evidence supporting the different measures.
14. Describe future directions and areas of research to enhance care after acute MI.
15. Review the current guidelines for catheter based revascularization in stable ischemic heart disease.
16. Evaluate the relevance and impact of the recent sham-controlled trial (ORBITA) of percutaneous coronary intervention (PCI) in stable ischemic heart disease.
17. Review the indications for referral for durable left ventricular assist devices (LVAD) consideration.
18. Identify the specific considerations and contraindications for durable LVAD implantation.
19. Discuss the clinical factors influencing the management of LVAD.
20. Evaluate the emergencies in patients with LVAD.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Oklahoma College of Medicine and the Oklahoma Chapter of the American College of Cardiology. The University of Oklahoma College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience:
Adult Cardiologists, Pediatric Cardiologists, Cardiothoracic Surgeons, Cardiology Fellows-in-Training, the entire Cardiac Care Team including but not limited to: Nurses, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistant, Pharmacists

Nondiscrimination Statement:
The University of Oklahoma, in compliance with all applicable federal and state laws and regulations does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, and educational services.

Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, University Equal Opportunity Office and Title IX Coordinator, (405) 325-3546, [email protected], or visit www.ou.edu/eoo.

Accommodation Statement:
Accommodations on the basis of disability are available by contacting Beth Quick-Andrews, C.A.E. at (314) 416-2240 or [email protected] as soon as possible.

Planning Committee Members: 
C.A. Sivaram, M.D., F.A.C.C. Course Director
Faisal Latif, MD FACC 
Beau Hawkins, MD FACC (Early Career Member)
Blake Morris, MD (Fellow)
Adam Burroughs MD (Fellow)
Beth Quick-Andrews, CAE - Course Contact

Conflict Resolution Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Oklahoma College of Medicine and the Oklahoma Chapter of the American College of Cardiology. The University of Oklahoma College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Disclaimer Statement:
Statements, opinions and results of studies contained in the program are those of the presenters, authors and joint provider and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty, Joint Provider and Presenters Disclosure:
It is the policy of the University of Oklahoma, College of Medicine that the faculty, presenters and joint provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). 

Venue Information:
The meeting site will be at the Rainbolt Family Auditorium in the Samis Education Center on the OU Health Sciences Center campus. 1200 Children’s Avenue, Oklahoma City, OK 73104

AMA PRA Category 1 Credits™ (6.00 hours), Non-Physician Attendance (6.00 hours)

Planning Committee Members

   C. A. Sivaram, MD, FACC     Bio
                        David Ross Boyd Professor & Vice Chief, Cardiovascular Section Director
                        Course Director

   Faisal Latif, MD, FACC     Bio
                      Assistant Professor of Medicine, University of Oklahoma
                      ACC Chapter President; Member, ACC Board of Governors

   Beau Hawkins, MD, FACC
                      Early Career Member

   Adam G Burroughs, MD   Bio
                      Cardiovascular Fellow

   Blake Morris, MD   Bio
                      Cardiovascular Fellow

   Beth Quick-Andrews, CAE   Bio
                      Oklahoma Chapter
                      Course Contact

Planning committee disclosures and resolutions will be available in the course syllabus.

Saturday, May 12, 2018

Commercial support is financial, or in-kind, contributions given by a commercial interest, which is used to pay all or part of the costs of a CME activity.  A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
This activity received no commercial or in-kind support.

Thank you to our 2018 Exhibitors:

Abbott
Amgen
Bard
Boston Scientific
Cardiovascular Systems, Inc. (CSI)
Chiesi
Kowa Pharmaceuticals
Lantheus Medical Imaging
Medtronic
Pfizer
Phillips
Teleflex
Worldwide Innovations & Technologies
Zoll